Cargando…

Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis

BACKGROUND AND OBJECTIVE: Severe aplastic anaemia (SAA) is a syndrome of bone marrow failure caused by T cell-mediated destruction of haematopoietic stem cells and progenitor cells. Whether patients with SAA should be treated with eltrombopag (EPAG) and immunosuppressive therapy (IST) or IST alone r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Senlin, Wang, Qingwei, Cui, Kai, Cheng, Bingjie, Fan, Junjie, Hu, Shaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198860/
https://www.ncbi.nlm.nih.gov/pubmed/37165250
http://dx.doi.org/10.1007/s40261-023-01266-7
_version_ 1785044819102400512
author Zhang, Senlin
Wang, Qingwei
Cui, Kai
Cheng, Bingjie
Fan, Junjie
Hu, Shaoyan
author_facet Zhang, Senlin
Wang, Qingwei
Cui, Kai
Cheng, Bingjie
Fan, Junjie
Hu, Shaoyan
author_sort Zhang, Senlin
collection PubMed
description BACKGROUND AND OBJECTIVE: Severe aplastic anaemia (SAA) is a syndrome of bone marrow failure caused by T cell-mediated destruction of haematopoietic stem cells and progenitor cells. Whether patients with SAA should be treated with eltrombopag (EPAG) and immunosuppressive therapy (IST) or IST alone remains debatable. Therefore, we conducted this meta-analysis to compare the efficacy of eltrombopag + IST with that of IST alone in patients with SAA and to assess the difference in the efficacy of eltrombopag in adults and children. METHODS: We performed this meta-analysis by retrieving studies that met the inclusion and exclusion criteria from PubMed, EMBASE, and the Cochrane Library up to 1 January 2023. We used a random-effects model to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for primary and secondary outcomes. I(2) statistics were used to evaluate the heterogeneity of the included studies. RESULTS: Six studies involving a total of 699 patients were included. In terms of the primary outcomes, our pooled results indicated that patients treated with EPAG + IST had a higher 6-month overall response rate (OR = 2.25; 95% CI, 1.60–3.16; p < 0.00001), a higher 6-month complete response rate (OR = 2.61; 95% CI, 1.82–3.74; p < 0.00001), and a lower 6-month nonresponse rate (OR = 0.32; 95% CI, 0.19–0.52; p < 0.00001). However, there was no significant difference in the rate of 6-month partial response (OR = 0.94; 95% CI, 0.49–1.81; p = 0.85). CONCLUSION: This meta-analysis indicated that patients treated with additional eltrombopag for IST may have a higher rate of haematological response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40261-023-01266-7.
format Online
Article
Text
id pubmed-10198860
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101988602023-05-21 Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis Zhang, Senlin Wang, Qingwei Cui, Kai Cheng, Bingjie Fan, Junjie Hu, Shaoyan Clin Drug Investig Systematic Review BACKGROUND AND OBJECTIVE: Severe aplastic anaemia (SAA) is a syndrome of bone marrow failure caused by T cell-mediated destruction of haematopoietic stem cells and progenitor cells. Whether patients with SAA should be treated with eltrombopag (EPAG) and immunosuppressive therapy (IST) or IST alone remains debatable. Therefore, we conducted this meta-analysis to compare the efficacy of eltrombopag + IST with that of IST alone in patients with SAA and to assess the difference in the efficacy of eltrombopag in adults and children. METHODS: We performed this meta-analysis by retrieving studies that met the inclusion and exclusion criteria from PubMed, EMBASE, and the Cochrane Library up to 1 January 2023. We used a random-effects model to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for primary and secondary outcomes. I(2) statistics were used to evaluate the heterogeneity of the included studies. RESULTS: Six studies involving a total of 699 patients were included. In terms of the primary outcomes, our pooled results indicated that patients treated with EPAG + IST had a higher 6-month overall response rate (OR = 2.25; 95% CI, 1.60–3.16; p < 0.00001), a higher 6-month complete response rate (OR = 2.61; 95% CI, 1.82–3.74; p < 0.00001), and a lower 6-month nonresponse rate (OR = 0.32; 95% CI, 0.19–0.52; p < 0.00001). However, there was no significant difference in the rate of 6-month partial response (OR = 0.94; 95% CI, 0.49–1.81; p = 0.85). CONCLUSION: This meta-analysis indicated that patients treated with additional eltrombopag for IST may have a higher rate of haematological response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40261-023-01266-7. Springer International Publishing 2023-05-11 2023 /pmc/articles/PMC10198860/ /pubmed/37165250 http://dx.doi.org/10.1007/s40261-023-01266-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Systematic Review
Zhang, Senlin
Wang, Qingwei
Cui, Kai
Cheng, Bingjie
Fan, Junjie
Hu, Shaoyan
Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
title Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
title_full Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
title_fullStr Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
title_full_unstemmed Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
title_short Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
title_sort efficacy of eltrombopag with immunosuppressive therapy versus immunosuppressive therapy alone on severe aplastic anaemia: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198860/
https://www.ncbi.nlm.nih.gov/pubmed/37165250
http://dx.doi.org/10.1007/s40261-023-01266-7
work_keys_str_mv AT zhangsenlin efficacyofeltrombopagwithimmunosuppressivetherapyversusimmunosuppressivetherapyaloneonsevereaplasticanaemiaasystematicreviewandmetaanalysis
AT wangqingwei efficacyofeltrombopagwithimmunosuppressivetherapyversusimmunosuppressivetherapyaloneonsevereaplasticanaemiaasystematicreviewandmetaanalysis
AT cuikai efficacyofeltrombopagwithimmunosuppressivetherapyversusimmunosuppressivetherapyaloneonsevereaplasticanaemiaasystematicreviewandmetaanalysis
AT chengbingjie efficacyofeltrombopagwithimmunosuppressivetherapyversusimmunosuppressivetherapyaloneonsevereaplasticanaemiaasystematicreviewandmetaanalysis
AT fanjunjie efficacyofeltrombopagwithimmunosuppressivetherapyversusimmunosuppressivetherapyaloneonsevereaplasticanaemiaasystematicreviewandmetaanalysis
AT hushaoyan efficacyofeltrombopagwithimmunosuppressivetherapyversusimmunosuppressivetherapyaloneonsevereaplasticanaemiaasystematicreviewandmetaanalysis